Company news
ChemoCentryx Inc. news in 2022
ChemoCentryx Inc.'s news releases, calls and decks from 2022, newest first.
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
October 16, 2022
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 4, 2022
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
August 23, 2022
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
July 4, 2022
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 5, 2022
ChemoCentryx Announces Changes to its Board of Directors
May 30, 2022
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
May 17, 2022
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
May 4, 2022
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
April 27, 2022
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
April 12, 2022
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
February 28, 2022
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
January 18, 2022